Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Therapeutic vaccines and immunological intervention in HIV infection

a paradigm change

Pantaleo, Giuseppe; Levy, Yves

Current Opinion in HIV and AIDS: November 2016 - Volume 11 - Issue 6 - p 576–584
doi: 10.1097/COH.0000000000000324
HIV VACCINE: Edited by Stephen J. Kent and Jerome H. Kim
Buy

Purpose of review The purpose is to review current knowledge of immunological interventions in HIV infection and discuss strategies for the establishment of functional cure and/or HIV eradication.

Recent findings Therapeutic vaccines and cytokines have been historically the immunological interventions developed with the objective to enhance the HIV-specific cell-mediated immune responses and to suppress virus replication. Both these interventions have shown only partial antiviral effects. The recent identification and generation of human broad neutralizing antibodies provides potent immunological intervention associated with effective suppression of virus replication in the absence of antiretroviral therapy. Furthermore, the identification that the major HIV cell reservoir containing replication competent and infectious virus is composed by programed cell death protein 1 (PD-1) positive memory CD4+ T cells offers the opportunity to target directly the HIV cell reservoir with anti-PD-1 antibodies. Anti-PD-1 antibody therapy may be also critical to prevent exhaustion of CD8+ T cells.

Summary The availability of a diverse armamentarium of immunological intervention offers the opportunity to investigate the efficacy of the combined use of different immunological interventions in inducing prolonged virus suppression in the absence of antiretroviral therapy and functional cure HIV or HIV eradication.

aService of Immunology and Allergy

bSwiss Vaccine Research Institute, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland

cINSERM U955, Paris Est Créteil University

dGroupe Hospitalier Henri-Mondor Albert-Chenevier

eVaccine Research Institute, Créteil, France

Correspondence to Professor Giuseppe Pantaleo, MD, PhD, Service of Immunology and Allergy, Swiss Vaccine Research Institute, Lausanne University Hospital, Lausanne, Switzerland. Tel: +41213141071; e-mail: giuseppe.pantaleo@chuv.ch and to Professor Yves Levy, MD, PhD, Clinical immunopathology, Faculté de Médecine de Créteil, Groupe Hospitalier Henri-Mondor Albert-Chenevier, INSERM U955, Vaccine Research Institute (VRI), 51, Avenue du Maréchal de Lattre de Tassigny, 94010 Créteil, France. Tel: +33 0 1 49 81 44 42; fax: +33 0 1 49 81 24 69; e-mail: yves.levy@aphp.fr

Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.